Understanding splenic haemangiosarcoma — a rapidly fatal cancer of dogs requiring careful welfare management.
Splenic haemangiosarcoma presents one of the most challenging welfare scenarios in veterinary oncology. The disease is typically silent until rupture — dogs appear normal until sudden collapse from internal haemorrhage. Emergency splenectomy saves the immediate crisis but histopathology reveals a cancer with extremely poor long-term prognosis.
The welfare conversation that follows diagnosis requires sensitivity. Owners must understand that the median survival with surgery plus chemotherapy is only 4-6 months, and that further tumour rupture (from cardiac or other primary sites) remains a risk. The quality of life during this period depends heavily on how the dog responds to chemotherapy and whether metastatic disease remains subclinical.
Compassionate end-of-life planning is essential. Regular reassessment using validated quality of life tools helps owners make timely decisions. Home euthanasia options should be discussed proactively, as sudden deterioration may occur.